Key clinical point: Prices of self-administered disease-modifying therapies for multiple sclerosis increased significantly from 2006 to 2016.
Major finding: Patients’ out-of-pocket costs increased by a factor of 7.2 during this period.
Study details: A cohort study of Medicare claims data from 2006 to 2016.
Disclosures: The Myers Family Foundation and the National Heart, Lung, and Blood Institute funded this research. Several authors are employees of health insurance companies such as the UPMC Health Plan Insurance Services Division and Humana. One author received personal fees from Pfizer that were unrelated to this study.